Scientific article
Open access

Médicaments génériques et biosimilaires : une panacée ?

Published inRevue médicale suisse, vol. 11, no. 490, p. 1909-1914
Publication date2015

Drugs are the third largest source of expenditure under Switzerland's compulsory basic health insurance. Generics, the price of which should be at least 30 per cent less than the cost of the original drugs, can potentially allow substantial savings. Their approval requires bioequivalence studies and their use is safe, although some factors may influence patients' and physicians' acceptance. The increased substitution of biosimilar drugs for more expensive biotech drugs should allow further cost savings. In an attempt to extend the monopoly granted by the original drug patent, some pharmaceutical companies implement "evergreening" strategies including small modifications of the original substance for which the clinical benefit is not always demonstrated.

  • Biosimilar Pharmaceuticals/administration & dosage/economics
  • Drug Costs
  • Drug Industry/economics
  • Drug Substitution/economics
  • Drugs
  • Generic/administration & dosage/economics
  • Humans
  • Patents as Topic
  • Switzerland
Citation (ISO format)
DALY, Marie-Josée, GUIGNARD, Bertrand, NENDAZ, Mathieu. Médicaments génériques et biosimilaires : une panacée ? In: Revue médicale suisse, 2015, vol. 11, n° 490, p. 1909–1914.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation04/23/2016 5:50:00 PM
First validation04/23/2016 5:50:00 PM
Update time03/15/2023 12:18:47 AM
Status update03/15/2023 12:18:47 AM
Last indexation05/02/2024 5:24:46 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack